We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+3.15%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.57B
AUM Growth
+$120M
Cap. Flow
+$109M
Cap. Flow %
6.95%
Top 10 Hldgs %
44.48%
Holding
133
New
28
Increased
33
Reduced
33
Closed
26

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$40.1M
2
CLDX icon
Celldex Therapeutics
CLDX
+$25.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$21.7M
4
HQY icon
HealthEquity
HQY
+$12.8M
5
ARKK icon
ARK Innovation ETF
ARKK
+$9.18M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$60.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$27.8M
3
CTLT
CATALENT, INC.
CTLT
+$24.5M
4
LH icon
Labcorp
LH
+$23.9M
5
MASI
Masimo
MASI
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 72.04%
2 Industrials 1.19%
3 Technology 0.06%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
51
Biogen
BIIB
$29.9B
$7.93M 0.51%
+33,041
New +$8.5M
TEVA icon
52
CALL
Teva Pharmaceuticals
TEVA
$35.9B
$7.71M 0.49%
962,400
– –
HZNP
53
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$7.54M 0.48%
70,000
– –
ARGX icon
54
argenx
ARGX
$57.4B
$7.53M 0.48%
21,496
+15,750
+274% +$4.79M
CERN
55
DELISTED
Cerner Corp
CERN
$7.22M 0.46%
+77,543
New +$5.9M
LQDA icon
56
Liquidia Corp
LQDA
$7.67B
$7.05M 0.45%
1,447,898
+518,849
+56% +$2.07M
IQV icon
57
IQVIA
IQV
$34.7B
$6.95M 0.44%
24,618
+17,828
+263% +$4.63M
XENE icon
58
Xenon Pharmaceuticals
XENE
$6.32B
$6.55M 0.42%
+209,519
New +$6.26M
ANAB icon
59
AnaptysBio
ANAB
$1.6B
$6.35M 0.41%
182,612
+104,558
+134% +$3.32M
RVTY icon
60
Revvity
RVTY
$12.3B
$6.21M 0.4%
30,869
-16,212
-34% -$2.93M
SIBN icon
61
SI-BONE Inc
SIBN
$737M
$5.73M 0.37%
258,094
+108,094
+72% +$2.33M
NVRO
62
DELISTED
NEVRO CORP.
NVRO
$5.36M 0.34%
+66,074
New +$6.62M
ZNTL icon
63
Zentalis Pharmaceuticals
ZNTL
$308M
$5.31M 0.34%
+63,163
New +$4.89M
MRK icon
64
Merck
MRK
$324B
$5.03M 0.32%
+19,456
New +$1.55M
AUPH icon
65
Aurinia Pharmaceuticals
AUPH
$1.97B
$4.61M 0.29%
+201,384
New +$4.77M
VRDN icon
66
Viridian Therapeutics
VRDN
$2.13B
$3.85M 0.25%
194,589
+34,589
+22% +$644K
MRK icon
67
CALL
Merck
MRK
$324B
$3.73M 0.24%
48,700
– –
MRVI icon
68
Maravai LifeSciences
MRVI
$997M
$3.68M 0.24%
87,795
-240,015
-73% -$9.72M
ISRG icon
69
Intuitive Surgical
ISRG
$121B
$3.53M 0.23%
9,825
+390
+4% +$134K
DXCM icon
70
DexCom
DXCM
$27.6B
$3.44M 0.22%
25,604
– –
PBYI icon
71
Puma Biotechnology
PBYI
$406M
$3.4M 0.22%
1,117,898
+719,958
+181% +$3.12M
LXRX icon
72
Lexicon Pharmaceuticals
LXRX
$1.02B
$3.14M 0.2%
797,694
-75,000
-9% -$364K
A icon
73
Agilent Technologies
A
$39.1B
$3.1M 0.2%
19,431
+771
+4% +$120K
CVAC
74
DELISTED
CureVac
CVAC
$2.92M 0.19%
+85,017
New +$3.42M
PGNY icon
75
PUT
Progyny
PGNY
$2.44B
$2.52M 0.16%
+50,000
New +$2.8M
1 2
3
4 5

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Eversept Partners held 133 positions worth $1.57B, up 8.3% from $1.45B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Eversept Partners deployed $109M of net new capital in Q4 2021, opening 28 new positions and adding to 33 existing holdings. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 315,129 shares worth $43.4M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 80% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Labcorp, an estimated $23.9M trimmed.

  • Eversept Partners's largest Q4 2021 buy was Biohaven Pharmaceutical Holding Company Ltd.: 315,129 shares worth $43.4M.
  • Eversept Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021, an estimated $21.7M increase.
  • Eversept Partners's biggest Q4 2021 reduction was Labcorp, cutting an estimated $23.9M.
  • Eversept Partners fully exited Acceleron Pharma in Q4 2021, selling an estimated $60.1M.
  • Eversept Partners's ten largest holdings make up 44% of its $1.57B portfolio in Q4 2021.
  • Eversept Partners opened 28 new positions and closed 26 in Q4 2021.
  • Eversept Partners's portfolio value rose 8.3% quarter-over-quarter to $1.57B.

Based on Eversept Partners's 13F filing for Q4 2021, filed 14 Feb 2022.